全文获取类型
收费全文 | 1520篇 |
免费 | 110篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 36篇 |
妇产科学 | 26篇 |
基础医学 | 188篇 |
口腔科学 | 63篇 |
临床医学 | 135篇 |
内科学 | 325篇 |
皮肤病学 | 29篇 |
神经病学 | 80篇 |
特种医学 | 50篇 |
外科学 | 223篇 |
综合类 | 60篇 |
一般理论 | 2篇 |
预防医学 | 184篇 |
眼科学 | 43篇 |
药学 | 96篇 |
中国医学 | 15篇 |
肿瘤学 | 75篇 |
出版年
2024年 | 2篇 |
2023年 | 33篇 |
2022年 | 92篇 |
2021年 | 131篇 |
2020年 | 68篇 |
2019年 | 75篇 |
2018年 | 94篇 |
2017年 | 56篇 |
2016年 | 61篇 |
2015年 | 64篇 |
2014年 | 66篇 |
2013年 | 76篇 |
2012年 | 108篇 |
2011年 | 135篇 |
2010年 | 72篇 |
2009年 | 58篇 |
2008年 | 70篇 |
2007年 | 80篇 |
2006年 | 60篇 |
2005年 | 49篇 |
2004年 | 42篇 |
2003年 | 36篇 |
2002年 | 38篇 |
2001年 | 5篇 |
2000年 | 8篇 |
1999年 | 10篇 |
1998年 | 6篇 |
1997年 | 2篇 |
1996年 | 4篇 |
1995年 | 4篇 |
1994年 | 1篇 |
1993年 | 4篇 |
1992年 | 4篇 |
1991年 | 1篇 |
1990年 | 2篇 |
1989年 | 2篇 |
1988年 | 5篇 |
1987年 | 4篇 |
1986年 | 3篇 |
1985年 | 3篇 |
1984年 | 1篇 |
1982年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1974年 | 1篇 |
1947年 | 1篇 |
1945年 | 1篇 |
排序方式: 共有1641条查询结果,搜索用时 0 毫秒
31.
Lo JC Mulligan K Noor MA Schwarz JM Halvorsen RA Grunfeld C Schambelan M 《The Journal of clinical endocrinology and metabolism》2001,86(8):3480-3487
GH has been proposed as a therapy for patients with HIV-associated fat accumulation, but the pharmacological doses (6 mg/d) used have been associated with impaired fasting glucose and hyperglycemia. In contrast, physiologic doses of GH ( approximately 1 mg/d) in HIV-negative men reduced visceral adiposity and eventually improved insulin sensitivity, despite initially causing insulin resistance. We conducted an open-label study to evaluate the effects of a lower pharmacologic dose of GH (3 mg/d) in eight men with HIV-associated fat accumulation. Oral glucose tolerance, insulin sensitivity, and body composition were measured at baseline, and 1 and 6 months. Six patients completed 1 month and 5, 6 months of GH therapy. IGF-I levels increased 4-fold within 1 month of GH treatment. Over 6 months, GH reduced buffalo hump size and excess visceral adipose tissue. Total body fat decreased (17.9 +/- 10.9 to 13.5 +/- 8.4 kg, P = 0.05), primarily in the trunk region. Lean body mass increased (62.9 +/- 6.4 to 68.3 +/- 9.1 kg, P = 0.03). Insulin-mediated glucose disposal, measured by a euglycemic hyperinsulinemic clamp, declined at month 1 (49.7 +/- 27.5 to 25.6 +/- 6.6 nmol/kg(LBM).min/pmol(INSULIN)/liter, P = 0.04); values improved at month 6 (49.2 +/- 22.6, P = 0.03, compared with month 1) and did not differ significantly from baseline. Similarly, the integrated response to an oral glucose load worsened at month 1 (glucose area under the curve 20.1 +/- 2.3 to 24.6 +/- 3.7 mmol.h/liter, P < 0.01), whereas values improved at month 6 (22.1 +/- 1.5, P = 0.02, compared with month 1) and did not differ significantly from baseline. One patient developed symptomatic hyperglycemia within 2 wk of GH initiation; baseline oral glucose tolerance testing revealed preexisting diabetes despite normal fasting glucose. In conclusion, GH at 3 mg/d resulted in a decrease in total body fat and an increase in lean body mass in this open-label trial. While insulin sensitivity and glucose tolerance initially worsened, they subsequently improved toward baseline. However, the dose of GH used in this trial was supraphysiologic and led to an increase in IGF-I levels up to three times the upper normal range. Because there are known adverse effects of long-term GH excess, the effectiveness of lower doses of GH should be studied. We also recommend a screening oral glucose tolerance test be performed to exclude subjects at risk for GH-induced hyperglycemia. 相似文献
32.
33.
Noor H. A. Suaini Evelyn Xiu-Ling Loo Rachel L. Peters Gaik Chin Yap Katrina J. Allen Hugo Van Bever David J. Martino Anne Eng Neo Goh Shyamali C. Dharmage Marjorelee T. Colega Mary Foong Fong Chong Anne-Louise Ponsonby Kok Hian Tan Mimi L. K. Tang Keith M. Godfrey Bee Wah Lee Lynette Pei-Chi Shek Jennifer J. Koplin Elizabeth Huiwen Tham 《Allergy》2021,76(10):3171-3182
34.
Noor Fatima Majeed Marta Braschi Amirfarzan Christoph Wald Jeremy R Wortman 《The British journal of radiology》2021,94(1123)
Objective:Spectral detector CT (SDCT) has many applications in advanced liver imaging. If appropriately utilized, this technology has the potential to improve image quality, provide new diagnostic information, and allow for decreased radiation dose. The purpose of this review is to familiarize radiologists with the uses of SDCT in liver imaging.Conclusion:SDCT has a variety of post-processing techniques, which can be used in advanced liver imaging and can significantly add value in clinical practice. 相似文献
35.
36.
Madigan Cory G. Adams Michael B. Chu Chu-Chiao Dinkha Laith R. Farrell Samuel J. Hoard Robert T. Keithler Andrea N. Loudermilk Kevin A. Rouse Jessica Walker Brandon L. Williams Susan G. Wyatt Andrew C. Gore Rosco S. Thomas Dustin M. 《The international journal of cardiovascular imaging》2021,37(12):3583-3588
The International Journal of Cardiovascular Imaging - To compare overall number of downstream tests and total costs between negative exercise stress echocardiograms (ESE) or cardiac computed... 相似文献
37.
38.
Psychometric properties of the revised Malay version Medical Outcome Study Social Support Survey using confirmatory factor analysis among postpartum mothers
下载免费PDF全文
![点击此处可从《Asia-Pacific psychiatry》网站下载免费的PDF全文](/ch/ext_images/free.gif)
39.
The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults 总被引:5,自引:0,他引:5
Noor MA Parker RA O'Mara E Grasela DM Currie A Hodder SL Fiedorek FT Haas DW 《AIDS (London, England)》2004,18(16):2137-2144
BACKGROUND: Therapy with some HIV protease inhibitors (PI) contributes to insulin resistance and type 2 diabetes mellitus, by inhibition of insulin-sensitive glucose transporters. Atazanavir (ATV) is a new PI with substantially less in vitro effect on glucose transport than observed with other PI, including lopinavir (LPV) or ritonavir (RTV). METHODS: Randomized, double-blind, crossover study of the effect of 5 days of administering ATV, lopinavir/ritonavir (LPV/r) or placebo on insulin-stimulated glucose disposal in 30 healthy HIV-negative subjects. Each subject was studied on two of three possible treatments with a wash-out period between treatments. RESULTS: The mean insulin-stimulated glucose disposal (mg/min per kg body weight) per unit insulin (microU/ml) (M/I) was 9.88, 9.80 and 7.52 for placebo, ATV and LPV/r, respectively (SEM, 0.84 for all). There was no significant difference between ATV and placebo. The M/I for LPV/r was 23% lower than that for ATV (P = 0.010) and 24% lower than that for placebo (P = 0.008). The mean glycogen storage rates were 3.85, 4.00 and 2.54 mg/min per kg for placebo, ATV and LPV/r, respectively (SEM, 0.39 for all). There was no significant difference between ATV and placebo. The glycogen storage rate for LPV/r was 36% lower than ATV (P = 0.003) and 34% lower than placebo (P = 0.006). CONCLUSIONS: ATV given to healthy subjects for 5 days did not affect insulin sensitivity, while LPV/r induced insulin resistance. This observation is consistent with differential in vitro effects of these PI on glucose transport. Further data are needed to assess clinical implications for body composition. 相似文献
40.
Cytomorphology of palpable breast lesions: Diagnostic utility of FNAC in a developing country
下载免费PDF全文
![点击此处可从《Diagnostic cytopathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)